These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 16086624

  • 1. Symptom clusters as predictors of late response to antidepressant treatment.
    Trivedi MH, Morris DW, Grannemann BD, Mahadi S.
    J Clin Psychiatry; 2005 Aug; 66(8):1064-70. PubMed ID: 16086624
    [Abstract] [Full Text] [Related]

  • 2. Which depressed patients respond to nefazodone and when?
    Trivedi MH, Rush AJ, Pan JY, Carmody TJ.
    J Clin Psychiatry; 2001 Mar; 62(3):158-63. PubMed ID: 11305700
    [Abstract] [Full Text] [Related]

  • 3. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [Abstract] [Full Text] [Related]

  • 4. Novel Augmentation Strategies in Major Depression.
    Martiny K.
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [Abstract] [Full Text] [Related]

  • 5. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression.
    Feighner J, Targum SD, Bennett ME, Roberts DL, Kensler TT, D'Amico MF, Hardy SA.
    J Clin Psychiatry; 1998 May; 59(5):246-53. PubMed ID: 9632036
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.
    Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markowitz JC, Miller I, Ninan PT, Rothbaum BO, Thase ME, Trivedi MH, Keller MB.
    Arch Gen Psychiatry; 2005 May; 62(5):513-20. PubMed ID: 15867104
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study.
    Saiz-Ruiz J, Ibañez A, Díaz-Marsá M, Arias F, Carrasco JL, Huertas D, Martín-Carrasco M, Moreno I, Rico-Villademoros F.
    CNS Drugs; 2002 May; 16(9):635-43. PubMed ID: 12153334
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E.
    JAMA; 2000 Jun 21; 283(23):3082-8. PubMed ID: 10865302
    [Abstract] [Full Text] [Related]

  • 13. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
    Jamerson BD, Krishnan KR, Roberts J, Krishen A, Modell JG.
    Psychopharmacol Bull; 2003 Jun 21; 37(2):67-78. PubMed ID: 14566216
    [Abstract] [Full Text] [Related]

  • 14. Residual symptoms and recurrence during maintenance treatment of late-life depression.
    Dombrovski AY, Mulsant BH, Houck PR, Mazumdar S, Lenze EJ, Andreescu C, Cyranowski JM, Reynolds CF.
    J Affect Disord; 2007 Nov 21; 103(1-3):77-82. PubMed ID: 17321595
    [Abstract] [Full Text] [Related]

  • 15. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
    Hirschfeld RM, Weisler RH, Raines SR, Macfadden W, BOLDER Study Group.
    J Clin Psychiatry; 2006 Mar 21; 67(3):355-62. PubMed ID: 16649820
    [Abstract] [Full Text] [Related]

  • 16. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S, Ferreri M, Cabanac F, Bitton M.
    Encephale; 2003 Mar 21; 29(5):438-44. PubMed ID: 14615693
    [Abstract] [Full Text] [Related]

  • 17. Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder.
    Lin CH, Lane HY, Chen CC, Juo SH, Yen CF.
    Clin J Pain; 2011 Mar 21; 27(9):805-10. PubMed ID: 21677571
    [Abstract] [Full Text] [Related]

  • 18. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
    Perugi G, Frare F, Toni C, Ruffolo G, Torti C.
    Neuropsychobiology; 2002 Mar 21; 46(3):145-9. PubMed ID: 12422062
    [Abstract] [Full Text] [Related]

  • 19. Does pretreatment insomnia or anxiety predict acute response to bupropion SR?
    Rush AJ, Carmody TJ, Haight BR, Rockett CB, Zisook S.
    Ann Clin Psychiatry; 2005 Mar 21; 17(1):1-9. PubMed ID: 15941026
    [Abstract] [Full Text] [Related]

  • 20. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M.
    Psychiatry Res; 2008 Oct 30; 161(1):116-20. PubMed ID: 18755514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.